1
|
Weng S, Matsuura S, Mowery CT, Stoner SA, Lam K, Ran D, Davis AG, Lo MC, Zhang DE. Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity. Leukemia 2016; 31:159-169. [PMID: 27389055 PMCID: PMC5214981 DOI: 10.1038/leu.2016.167] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Revised: 05/19/2016] [Accepted: 05/23/2016] [Indexed: 02/06/2023]
Abstract
GM-CSF signaling regulates hematopoiesis and immune responses. CSF2RA, the gene encoding the α subunit for GM-CSF, is significantly downregulated in t(8;21) (RUNX1-ETO or RE) leukemia patients, suggesting that it may serve as a tumor suppressor. We previously reported that GM-CSF signaling is inhibitory to RE leukemogenesis. Here we conducted gene expression profiling of primary RE hematopoietic stem/progenitor cells (HSPCs) treated with GM-CSF to elucidate the mechanisms mediating the negative effects of GM on RE leukemogenicity. We observed that GM treatment of RE HSPCs resulted in a unique gene expression profile that resembles primary human cells undergoing myelopoiesis, which was not observed in control HSPCs. Additionally we discovered that GM-CSF signaling attenuates MYC-associated gene signatures in RE HSPCs. In agreement with this, a functional screen of a subset of GM-CSF-responsive genes demonstrated that a MYC inhibitor, MXI1, reduced the leukemic potential of RE HSPCs and t(8;21) AML cells. Furthermore, MYC knockdown and treatment with the BET inhibitor JQ1 reduced the leukemic potential of t(8;21) cell lines. Altogether, we discovered a novel molecular mechanism mediating the GM-CSF-induced reduction in leukemic potential of RE cells, and our findings support MYC inhibition as an effective strategy for reducing the leukemogenicity of t(8;21) AML.
Collapse
Affiliation(s)
- S Weng
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - S Matsuura
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - C T Mowery
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - S A Stoner
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - K Lam
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - D Ran
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - A G Davis
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - M-C Lo
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - D-E Zhang
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.,Department of Pathology and Division of Biological Sciences, University of California San Diego, La Jolla, CA, USA
| |
Collapse
|